Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | USP2 | O75604 | 1/20 | 0.87 |
| ▸ | POLB | P06746 | 1/20 | 0.87 |
| ▸ | PPARG | P37231 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.87 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.49 |
| ▸ | APLNR | P35414 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356182 | 1.00 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29355331 | 0.93 | MEN1 (1.00) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL16593265 | 0.93 | MEN1 (1.00) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL1083748 | 0.92 | MEN1 (0.74) | MEN1USP2POLBPPARGBLM | |
| Water SCHEMBL7715721 | 0.92 | MEN1 (0.98) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL29352150 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL18483 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL31011003 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL31011004 | 0.91 | MEN1 (0.87) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL15384055 | 0.89 | MEN1 (0.69) | MEN1USP2POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11497757-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2019-06-20 | — | — | US | disclosed |
| US-10293053-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190111142-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-9766213-B2 | Innovation to assay mixing | BIO-RAD LABORATORIES, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20150090343-A1 | INNOVATION TO ASSAY MIXING | BIO-RAD LABORATORIES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8865130-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2013-02-28 | — | — | US | disclosed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | MEN1 2446/4885USP2 1953/4885POLB 2465/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
| US-11497757-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | MEN1 2446/4885USP2 1953/4885POLB 2465/4885 |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | MEN1 2446/4885USP2 1953/4885POLB 2465/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
| US-10716801-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | MEN1 2446/4885USP2 1953/4885POLB 2465/4885 |
| US-10293053-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | MEN1 2446/4885USP2 1953/4885POLB 2465/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MEN1 380/4885USP2 735/4885POLB 3269/4885 |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | MEN1 3725/4885USP2 863/4885POLB 2180/4885 |
| US-20190111142-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | MEN1 2446/4885USP2 1953/4885POLB 2465/4885 |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | CD47, CD4, BST2 | MEN1 2446/4885USP2 1953/4885POLB 2465/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | MEN1 4291/4885USP2 2631/4885POLB 3293/4885 |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | MEN1 3725/4885USP2 863/4885POLB 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.